What does this research mean for the field?

Hepatic arterial infusion chemotherapy (HAIC) is effective and well-tolerated in patients with mismatch repair proficient/microsatellite stable colorectal cancer liver metastases who are refractory to systemic therapy. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of hepatic arterial infusion chemotherapy in pMMR/MSS colorectal cancer liver metastases.

March 12, 2026Open Access

The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy for Mismatch Repair Proficient ( pMMR )/Microsatellite Stable ( MSS ) Colorectal Cancer Liver Metastases ( CRLM )

Key Points

To evaluate the efficacy and safety of hepatic arterial infusion chemotherapy in pMMR/MSS colorectal cancer liver metastases.
Conducted analysis on patients undergoing HAIC for colorectal cancer liver metastases
Evaluated effectiveness and tolerance of HAIC in patients refractory to systemic therapy
Investigated the potential additive value of targeted therapy alongside HAIC
HAIC shown to be effective and well-tolerated in treated patients
Patients demonstrated a response despite previous systemic therapy failures
Further research needed to assess synergy with targeted therapy

Abstract

HAIC shows effectiveness and tolerance in pMMR/MSS CRLM patients who are refractory to systemic therapy. However, the additive value of targeted therapy for HAIC in these patients needs to be further investigated.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper